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The cell cycle and sucl: from structure to function?
Structures have recently been determined for the yeast Schizosaccharomyces pombe
cell cycle regulatory protein, CKS/sucl, and its human equivalent. The structures
provide some long-awaited clues about the role of CKS/sucl in cell cycle control.
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The product of the sucl gene, pl3SUCl, is essential for the
function of the cell cycle regulatory protein kinase
p34cdc 2 in vivo. It was originally identified in the yeast
Schizosaccharomyces pombe through its ability, in high copy
number, to suppress the temperature-sensitive phenotype
of certain cdc2 mutants [1]. Since then, pl3Sucl homo-
logues, as judged by both sequence and functional simi-
larity, and called CKS proteins (for CDC28 kinase
subunit), have been identified in a number of other
species [2-4]. pl3SUCl has no known catalytic activity and
extensive searches for sequence homology with proteins
of known function have been unsuccessful. It is used
extensively in cell cycle studies as an affinity agent for the
p3 4cdc2 kinase. But, nearly a decade after its original
characterization, we still do not have a satisfactory
description of its activity.
In both the yeasts S. pombe [5-7] and Saccharomyces cere-
visiae [3] pl3SUcl is essential for cell viability. Overexpres-
sion of pl3sucl in vivo has less dramatic effects than
disruption of its expression: cells show a slight delay in
entry into mitosis [7]. It has been proposed from in vitro
studies that this phenotype results from inhibition of
CDC25-dependent dephosphorylation of p34cdc2 on
residue Tyrl5 [8]. This residue lies within the p34cdc 2
kinase active-site cleft, and its dephosphorylation
(together with that of Thrl4 in higher eukaryotes)
accompanies p34 cdc2 kinase activation on entry into the
mitotic (M) phase of the cell cycle (for review, see [9]).
p13suc' has now been brought back into the cell cycle fray
with the recent determination by X-ray crystallographic
analysis of both the human p9CKS2 [10] and the S. pombe
p13suc 1 [11] structures. Overall the two proteins show
remarkably similar protein folds (Fig. 1). Both structures
are dominated by a four-stranded -sheet. 3 strands 1 and
2 (1 and 132) are separated in the linear sequence from
33 and 34 by -helical regions which, in the three-
dimensional structure, lie to one edge of the sheet. The
additional sequences in the larger pl3 suc l structure encode
a long ca-helix in the N-terminal region and an exposed
surface loop between 3 and (o4 (Fig. la). What has
turned out to be a complete structural surprise is the ori-
gins of the sequences which make up each fold. Whereas
the pl3sU cl structure is a monomer (Fig. la), the p9CKS2
structure has an unusual 3-strand exchange between adja-
cent molecules (Fig. lb). Without distorting the overall
fold, this strand exchange manages to create an intimate
dimer where 34 in each monomer originates from its
Fig. 1. Structures of pl3SUCl and a comparison with p9cKS2.
(a) p13SUCl is colour-ramped from blue to red over residues
21-101. Major insertions in pl3Sucl compared with p9cKS2 are
coloured white and labelled i for the a-helical region (residues
6-20), and i2 for the exposed surface loop (residues 56-65).
Secondary-structure elements are drawn as arrows (for
13-strands) or spirals (for a-helices), and are labelled. (b) One
subunit of the p9CKs2 dimer (subunit A) is colour-ramped from
blue to red over residues 2-79, and is drawn in the same car-
toon style as pl 3SCl. The other subunit is drawn in pink 'worm'
representation except for 14 which forms part of the 3-sheet of
the A subunit. The figure was prepared with the program XOB-
JECTS and the Ca coordinates for p9CKS2 were extracted from
published stereo pictures [10] using the program EXTRACT
(M Noble, personal communication).
dimer partner. In the p9CKS2 crystal structure this dimer
oligomerizes to create a hexameric ring stabilized by 31
and 33 inter-subunit hydrogen bonds [10].
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In the absence of a biochemically characterized catalytic
site, the identification of amino acids that are conserved
across species, and their localization on the protein struc-
ture, may highlight biologically important surface
regions. Just such an analysis has revealed two striking
clusters of conserved amino acids on the surface of
pl3 suc' [10,11]. The first creates a large aromatic and
hydrophobic surface dominating one face of the p13sucl
monomer (Fig. 2). The second is a cluster of positively
charged residues. Do these clusters represent the pl3 sudc
binding site for the p34 cdc2 kinase?
Fig. 2. (a) Amino acid conservation between p13suc' and its
homologues in S. cerevisiae, human and Patella vulgata at the
'hydrophobic patch' site. The pl 3s5C molecular surface was gen-
erated with GRASP [221. Surface residues conserved among all
five sequences are coloured in white, non-identical residues are
shown in blue. The view of p1 3sucl shown here is identical to
that in Fig. la. (b) The hydrophobic nature of the conserved
pl 3UC region. Hydrophobic amino acids (Ala, Cys, Phe, lie,
Leu, Met, Val, Pro, Tyr, Trp) are coloured white, whereas the
remaining amino acids are blue.
The group that determined the p9CKS2 structure propose
that one of these conserved amino acid clusters is impor-
tant for binding [10]. A sulphate ion is bound to the con-
served, positively charged site in 'the p9 CKS2 hexamer.
Parge et al. [10] suggest that binding of this sulphate ion
mimics binding of the phosphate group on p34cdc2 kinase
residue Thrl61 (Thr167 in S. pombe). In addition to
being phosphorylated on Thrl4 and Tyrl5 in its catalytic
site, p34 cdc2 kinase is also phosphorylated on Thrl61
after it becomes transiently associated with cyclin during
the cell cycle, and this event may aid stabilization of the
cyclin-p34cdc 2 complex (for review, see [12]). Using the
catalytic core region (residues 40-297) of the cAMP-
dependent protein kinase (cAPK) structure [13] as a
structural model for active p34 cdc2 kinase [14], Parge et
al. [10] describe modelling studies which show that the
active p34 cdc2 kinase model structure can be docked onto
hexameric p9CKS2 through the p34 cdc2 kinase Thrl61
phosphate group without steric hinderance. Based on
this structural analysis, Parge et al. propose an elegant
model for p9CKS2 function: by influencing p34cdc 2
oligomerization, p9CKS2 could act to regulate or localize
p34cdc2 kinase activity [10]. The structure of non-phos-
phorylated CDK2, another cyclin-dependent kinase,
closely related in sequence to p3 4 cdc2 has recently been
determined by X-ray crystallographic analysis [15]. This
structure confirms that cAPK and CDK2 have extensive
structural similarity, which is not inconsistent with the
proposed p9CKS2 interaction with p34cdc2
How well do the results of mutational analysis of p3 4 cdc2
kinase support this docking model? Human p34cdc 2
kinase has been subjected to extensive alanine-scanning
mutagenesis to identify regions that interact with pl3suc1
[16]. There are also a number of temperature-sensitive
S. pombe cdc2 mutant strains that are rescued at their
restrictive temperature by sucl+ overexpression [7]. Two
papers that describe the modelling of p34cdc2 on the crys-
tallographic coordinates of the cAPK catalytic subunit
[13] also describe the localization of these mutant sites on
the proposed active p34 cdc2 kinase structure [14,17]. All of
the S. pombe temperature-sensitive p34 cdc2 mutations map
to the large lobe of the kinase (Fig. 3). The results of ala-
nine-scanning mutagenesis would agree with the above
result and considerably extend the pl3suc1-binding region
to include residues in [52, distal to the glycine loop of the
ATP-binding site in the small N-terminal lobe, and
residues at the end of the conserved PSTAIRE sequence
(Fig. 3a,b). Groups of alanine-scanning mutations that
include residues conserved between p34cdc2 and cAPK,
and that are important for maintaining the structural
integrity of the large lobe, are also implicated in binding
pl3SUcl . The temperature-sensitive cdc2 mutation sites (red
in Fig. 3a) are not classed as solvent-accessible residues.
These results suggest that mutations that generally affect
the structural stability of p3 4 cdc2 may (indirectly) affect
pl3 sudl binding. Taken together, these studies suggest that
in addition to an interaction of p9CKS2 with a phosphory-
lated residue, as has been proposed, there is an extensive
surface of protein-protein interaction [10].
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Fig. 3. The CDK2 molecular surface high-
lighting the positions of residues impli-
cated in CDC2-pl3sucl binding. The
X-ray crystallographically determined
CDK2 structure [151 is used here as a
model for the CDC2 structure. The mol-
ecular surface was generated with GRASP
1221. (a) 'Front' view of the CDK2 mol-
ecular surface. The bound ATP molecule
at the partially formed active-site cleft is
shown in blue, but the T-loop sequences
at the front of the cleft partially obscure
the ATP molecule from view. The amino
acids that are mutated in temperature-
sensitive S. pombe cdc2 mutant strains
rescued by pl 3sucl overexpression are
highlighted in red; potential sites of
p34cdc2 _pl 3sucl interaction identified by
alanine-scanning mutagenesis are in
magenta. Residues in the insertion
sequence in CDK2 and CDC2 (relative to
alignment with other serine/threonine
kinases), the deletion of which decreases pl 3sUC binding to human p34cdc2 in vitro, are in green. As multiple amino acid changes are
introduced by both alanine-scanning and deletion analysis, the regions highlighted in magenta and green may give an inflated view of
the region important for pl 3 suclp 34 cdc2 interaction. (b) 'Back' view of the CDK2 molecule following a 180° rotation in y.
The modelled environment of the phosphorylated p34cdc2
Thrl61 residue, however, suggests that CKS/sucl may
not bind to active p34 cdc2 kinase through this residue.
Although the cAPK and CDK2 structures show extensive
similarity, there are important differences 1151. Non-
phosphorylated CDK2 is in an inactive conformation as a
result of structural impediments to activity, notably the
blocking of access to the catalytic cleft for substrate by the
'T-loop' sequence [15]. Activation of CDK2 requires
cyclin binding, followed by phosphorylation of ThrI60
[181 (the CDK2 homologue of human p34cdc2 Thrl61).
This threonine residue is within the T-loop sequence and
it can be envisaged that its phosphorylation may be
required at least to remove the T-loop from the catalytic
cleft and to stabilize the active conformation [15]. How
might the phosphorylation of Thrl6l achieve this goal?
Again, the active cAPK structure may provide a template
for understanding the active p34 cdc2 kinase structure.
Thrl61 can be modelled as the p3 4cdc2 homologue of
cAPK Thr197. Phosphorylated Thrl97 interacts with
conserved residues on both lobes to stabilize the active-
site cleft (Fig. 4a). Modelling studies of p3 4cdc2 show that
phosphorylation of Thrl61 could fulfil a similar role and
anchor the T-loop sequence to form the base of the cat-
alytic cleft (Fig. 4b). Conserved p34 cdc2 kinase residues
from both the small and the large lobes are in a position
to interact with the Thrl61 phosphate group. This mod-
elled alignment of the two kinase structures in this region
would be particularly satisfying because it also places the
conserved Thrl66 in the p3 4cdc2 sequence in a homolo-
gous position to Thr201 in cAPK. A recent comparative
structural analysis of cAPK with the human insulin
Fig. 4. The interactions at the Thr197 phosphorylation site in the
cAPK structure compared with those predicted for the homologous
residue Thrl 61 in human p34cdc2. (a) The cAPK structure; for clar-
ity, the only cAPK residues shown are phosphorylated Thr197,
Arg165, Lysl89, His87, Tyr215 and ThrI95. (b) Modelled human
p34cdc 2 structure. The p34cdc2 model 1171 was derived from the
cAPK structure. The phosphate group on Thr161 has not been
modelled into the structure. Only residues homologous to those in
(a) are shown, namely, residues Thrl61, Argl27, Argl51, Arg50,
TyrI 81 and Val 159. (Figure drawn using XOBJECTS.)
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Fig. 5. Comparative structural align-
ment of conserved residues in the
p1 3s Cl 'charged cluster' site with
residues important for phosphotyrosine
binding to the SH2 domain from v-Src.(a) pl 3UC structure. (b) v-Src structure.
Residues in the two structures were
optimally aligned using 'O' [23]. Phos-
photyrosine has been modelled into the
p1 3 sUCl structure. The conserved
p1 3sUc residues Arg39, Arg30, Arg99,
Ser79 are equivalent to v-Src Arg175,
Arg155, Lys203 and Thr179, respec-
tively. ThrI80 in v-Src is replaced by
the carbonyl oxygen of Leu80 in
p1 3sUC and v-Src Cys185 and Ser177
and mimicked by the conserved
p1 3sucl Trp82 residue.
receptor tyrosine kinase domain [19] suggests that a
threonine at this position in serine/threonine kinases may
play a crucial role in determining serine/threonine versus
tyrosine kinase specificity, by bringing key residues closer
together at the catalytic site via its conserved interactions
with Asp166 (the catalytic base, equivalent to p34 cdc2
Asp128) and Lys168 (p34cdc 2 residue Lysl30).
If the charged cluster site of pl3sU Cl and p9cKS2 does
bind a phosphorylated p34cdc2 residue, we have proposed
phosphorylated Tyrl5 as an alternative candidate [11].
Using the cAPK structure as a model for p34cdc2 kinase
suggests that Tyrl5 will be exposed once the T-loop is
removed from the cleft following Thrl61 -phosphoryla-
tion. Intriguingly, the three conserved pl3sucl arginine
residues in the charged cluster site can be superimposed
on the key residues in the SH2 domain of v-Src that bind
to phosphotyrosine [20]. This superimposition of the
two structures then aligns additional conserved residues
present in both sites (Fig. 5).
That pl3suC' is a phosphotyrosine-binding protein is a
novel idea. Although proposed on the basis of an analysis
of its crystal structure, this idea would be consistent with
earlier experiments showing that both in vitro and in vivo
an excess of pl3 suc can inhibit p34cdc2 kinase activation
[7,8]. An association of pl3sucl with phosphorylated
Tyrl5 may block access of the p80cdc25-encoded tyrosine
phosphatase, thus preventing dephosphorylation and acti-
vation of the protein kinase. However, pl3s ucl binds to
active p34 cdc2 kinase, so an additional binding interaction
must take place between the two proteins to stabilize the
complex in the absence of phosphorylated Tyrl5. This
interaction may occur at the conserved aromatic and
hydrophobic patch.
Two binding sites on p34 cdc2 for pl3sucl? The idea is not
new [21]. How might this be achieved? Going back to
the p9C KS2 and pl3 suCI structures may provide the
answer. The latter has been characterized as a monomer
and the former as a strand-exchanged dimer. The pro-
posed phosphotyrosine-binding site is present in both the
monomer and dimer structures. In the dimer structure,
however, one of the conserved residues in the site,
Arg71, originates from the other molecule as a result of
the P4-strand exchange (see Figs lb,5a). Because residues
of the 'hydrophobic and aromatic patch' site form a
hinge in the p9cKS2 dimer, and a turn in the pl3sUCl
monomer, the nature of this site depends on the
oligomerization state of the protein (Fig. 1). pl3SUCl may
bind to p34cdc2 as a monomer through the hydrophobic
and aromatic patch site. The two proposed p13SU cl
domains that may bind to p3 4 cdc2 (the hydrophobic and
aromatic patch site and the proposed phosphotyrosine-
binding site) need not originate from the same pl3SUCl
molecule. Furthermore, structural studies now show that
CKS/sucl can have alternative structures. The deter-
mination of whether CKS/sucl is a monomer or a dimer
may affect the additional binding of the protein to
p34cdc2 through the p34cdc 2 phosphorylated-Tyrl 5
residue. For cell cycle model cartoonists, a vista of cre-
ativity lies ahead. In the meantime, a number of very
interesting experiments suggest themselves. Nearly a
decade after its discovery, p13SUcl is back. It won't be
described as the small, stable protein of no known func-
tion for long.
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